Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kymera Therapeutics Inc KYMR

Healthcare Biotechnology
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small... see more

Recent & Breaking News (NDAQ:KYMR)

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

GlobeNewswire 22 hours ago

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

GlobeNewswire 7 days ago

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

GlobeNewswire November 26, 2024

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire November 5, 2024

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire October 31, 2024

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

GlobeNewswire October 24, 2024

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

GlobeNewswire October 23, 2024

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

GlobeNewswire October 23, 2024

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

GlobeNewswire October 9, 2024

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

GlobeNewswire September 25, 2024

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire August 28, 2024

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire August 21, 2024

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

GlobeNewswire August 19, 2024

Kymera Therapeutics Announces Proposed Public Offering

GlobeNewswire August 19, 2024

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire August 7, 2024

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

GlobeNewswire July 31, 2024

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

GlobeNewswire July 9, 2024

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

GlobeNewswire July 8, 2024

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

GlobeNewswire June 14, 2024

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

GlobeNewswire June 1, 2024